FY2025 Earnings Estimate for ASP Isotopes Inc. (NASDAQ:ASPI) Issued By HC Wainwright

ASP Isotopes Inc. (NASDAQ:ASPI) – Stock analysts at HC Wainwright issued their FY2025 earnings per share (EPS) estimates for shares of ASP Isotopes in a research note issued to investors on Wednesday, April 17th. HC Wainwright analyst H. Ihle forecasts that the company will post earnings per share of ($0.07) for the year. HC Wainwright currently has a “Buy” rating and a $5.50 target price on the stock. The consensus estimate for ASP Isotopes’ current full-year earnings is $0.07 per share.

ASP Isotopes Stock Performance

Shares of NASDAQ ASPI opened at $3.09 on Thursday. The company has a quick ratio of 1.85, a current ratio of 1.85 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $151.17 million, a price-to-earnings ratio of -6.31 and a beta of 5.03. The stock’s fifty day simple moving average is $3.67 and its 200 day simple moving average is $2.39. ASP Isotopes has a 52-week low of $0.28 and a 52-week high of $4.97.

Institutional Trading of ASP Isotopes

Several hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its position in shares of ASP Isotopes by 761.7% in the fourth quarter. Vanguard Group Inc. now owns 176,314 shares of the company’s stock worth $316,000 after buying an additional 155,853 shares during the last quarter. Virtu Financial LLC bought a new position in ASP Isotopes during the fourth quarter valued at about $26,000. GSA Capital Partners LLP acquired a new stake in ASP Isotopes during the fourth quarter valued at approximately $608,000. Citadel Advisors LLC acquired a new stake in ASP Isotopes during the fourth quarter valued at approximately $187,000. Finally, Rathbones Group PLC acquired a new stake in ASP Isotopes during the fourth quarter valued at approximately $272,000. Institutional investors and hedge funds own 16.80% of the company’s stock.

Insider Buying and Selling

In other ASP Isotopes news, Director Robert John Andrew Ryan bought 15,596 shares of the firm’s stock in a transaction dated Monday, January 29th. The stock was acquired at an average price of $2.35 per share, with a total value of $36,650.60. Following the completion of the transaction, the director now directly owns 537,055 shares in the company, valued at approximately $1,262,079.25. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 26.30% of the company’s stock.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.